Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

82.63
-2.4800-2.91%
Pre-market: 82.57-0.0600-0.07%05:12 EDT
Volume:3.67M
Turnover:304.54M
Market Cap:11.64B
PE:-36.18
High:87.20
Open:84.65
Low:82.16
Close:85.11
52wk High:95.49
52wk Low:27.94
Shares:140.86M
Float Shares:122.00M
Volume Ratio:2.80
T/O Rate:3.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:25.00
PE(LYR):-6,776.84

Loading ...

Citi adds ‘upside 30-day catalyst watch’ on Arrowhead

TIPRANKS
·
Yesterday

Citigroup Initiates Arrowhead Pharmaceuticals at Buy With $108 Price Target

MT Newswires Live
·
Sep 08

Arrowhead Pharmaceuticals : Citigroup Initiates Coverage with Buy Rating; Target Price $108

THOMSON REUTERS
·
Sep 08

U.S. Research Roundup-Fedex Freight Holding Company, PDF Solutions, Robinhood Markets

Reuters
·
Sep 08

This Biotech Wins a Big FDA Approval. Why Wall Street is Shrugging.

Dow Jones
·
Sep 05

Arrowhead Pharma to Present at Cantor Global Healthcare Conference

Reuters
·
Sep 03

Arrowhead Pharmaceuticals' sHTG Therapy Could Get FDA Approval by Q2 2027, RBC Says

MT Newswires Live
·
Aug 31

Arrowhead Pharmaceuticals Price Target Maintained with a $100.00/Share by RBC Capital

Dow Jones
·
Aug 31

Arrowhead Pharmaceuticals Posts ESC 2026 Investor Presentation on Shasta-3 and Shasta-4 Results

Reuters
·
Aug 31

Sector Update: Healthcare

MT Newswires Live
·
Aug 31

Arrowhead Pharmaceuticals' Plozasiran Meets Endpoints in Studies of Patients With Severe Hypertriglyceridemia

MT Newswires Live
·
Aug 31

Arrowhead Phase 3 SHASTA-3, SHASTA-4 studies met primary endpoints

TIPRANKS
·
Aug 31

Arrowhead Pharmaceuticals - Plozasiran Demonstrated Favorable Safety and Tolerability Profile in Phase 3 Studies

THOMSON REUTERS
·
Aug 30

Arrowhead Pharmaceuticals - to File Supplemental Nda with U.S. FDA by Year-End 2026 Using Priority Review Voucher

THOMSON REUTERS
·
Aug 30

Arrowhead Pharmaceuticals Presents Phase 3 Shasta-3 and Shasta-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia

THOMSON REUTERS
·
Aug 30

Arrowhead Pharma Director Michael S. Perry Disposes of 11,600 Shares for $1.01 Million

Reuters
·
Aug 21

Arrowhead announces availability of REDEMPLO for FCS in Germany

TIPRANKS
·
Aug 17

People Living with Familial Chylomicronaemia Syndrome (Fcs) in Germany Have Access to Redemplo® (Plozasiran) as a New Treatment Option to Reduce Triglycerides

THOMSON REUTERS
·
Aug 17

Arrowhead Pharmaceuticals Earnings Call Signals Confident Expansion

TIPRANKS
·
Aug 16

How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening Losses

Simply Wall St.
·
Aug 11